Endothelial Cell-Specific Molecule-1 Inhibits Albuminuria in Diabetic Mice
- 29 December 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (12) , 2059-2076
Abstract
Key Points: Circulating endothelial cell-specific molecule-1 (Esm-1) inversely correlates with diabetic kidney disease. Addition of Esm-1 in susceptible mice reduces albuminuria, and deletion of Esm-1 in resistant mice mildly worsens albuminuria. Esm-1 attenuates podocyte injury and select IFN signaling, highlighting innate immunity as a potential mechanism of kidney disease. Background: Diabetic kidney disease (DKD) is the most common cause of kidney failure in the world, and novel predictive biomarkers and molecular mechanisms of disease are needed. Endothelial cell-specific molecule-1 (Esm-1) is a secreted proteoglycan that attenuates inflammation. We previously identified that a glomerular deficiency of Esm-1 associates with more pronounced albuminuria and glomerular inflammation in DKD-susceptible relative to DKD-resistant mice, but its contribution to DKD remains unexplored. Methods: Using hydrodynamic tail-vein injection, we overexpress Esm-1 in DKD-susceptible DBA/2 mice and delete Esm-1 in DKD-resistant C57BL/6 mice to study the contribution of Esm-1 to DKD. We analyze clinical indices of DKD, leukocyte infiltration, podocytopenia, and extracellular matrix production. We also study transcriptomic changes to assess potential mechanisms of Esm-1 in glomeruli. Results: In DKD-susceptible mice, Esm-1 inversely correlates with albuminuria and glomerular leukocyte infiltration. We show that overexpression of Esm-1 reduces albuminuria and diabetes-induced podocyte injury, independent of changes in leukocyte infiltration. Using a complementary approach, we find that constitutive deletion of Esm-1 in DKD-resistant mice modestly increases the degree of diabetes-induced albuminuria versus wild-type controls. By glomerular RNAseq, we identify that Esm-1 attenuates expression of kidney disease–promoting and interferon (IFN)-related genes, including Ackr2 and Cxcl11. Conclusions: We demonstrate that, in DKD-susceptible mice, Esm-1 protects against diabetes-induced albuminuria and podocytopathy, possibly through select IFN signaling. Companion studies in patients with diabetes suggest a role of Esm-1 in human DKD.Keywords
All Related Versions
This publication has 95 references indexed in Scilit:
- Upregulation of Endocan by Epstein-Barr Virus Latent Membrane Protein 1 and Its Clinical Significance in Nasopharyngeal CarcinomaPLOS ONE, 2013
- Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db MicePLOS ONE, 2013
- In Vivo Screening for Secreted Proteins That Modulate Glucose Handling Identifies Interleukin-6 Family Members as Potent Hypoglycemic AgentsPLOS ONE, 2012
- Role of the Polarity Protein Scribble for Podocyte Differentiation and MaintenancePLOS ONE, 2012
- Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 DiabetesNew England Journal of Medicine, 2011
- Macrophages in the Pathogenesis of AtherosclerosisCell, 2011
- Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7Proceedings of the National Academy of Sciences, 2007
- Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathyClinical and Experimental Immunology, 2007
- Macrophage accumulation in human progressive diabetic nephropathyNephrology, 2006
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003